Gefitinib restores epidermal-growth-factor (EGF-)induced CXCL14/BRAK repression with a concomitant decrease in the level of phosphorylated EGF receptor (EGFR) and extracellular signal-regulated kinase (ERK). Nearly confluent HSC-3 cells were incubated with or without gefitinib (1 μM) and/or EGF (10 ng/mL). (a) Cells were incubated with EGF for 15 min for detection of EGF receptor (EGFR), phosphorylated EGFR (pEGFR), ERK, phosphorylated ERK (pERK), Akt and phosphorylated Akt (pAKT) levels and for 24 h to detect the BRAK protein level. Their protein levels were determined by western blotting after treatment with respective antibodies. Relative intensities for BRAK (b) and phosphorylated levels of Akt (pAKT, (c)), ERK (pERK, (d)), and EGFR (pEGFR, (e)) were normalized by -tubulin and their total proteins, respectively. ** (Student’s t-test); values are presented as mean SD ( in all panels). (Cited from [3]).